Search Results

In the presence of the esteemed Christopher Skeete, Minister for the Economy, and Christine Poirier, Laval City Councillor, , Corealis Pharma Inc. proudly inaugurates the expansion of its facilities nestled in the heart of Laval’s Biotech City.

Canadian company GRB Technologies today unveiled the results of a study of the LIBU germicidal elevator button conducted by the CHU de Québec-Université Laval Research Center.

Laser Medical Canada of Laval, Quebec, has pleaded guilty to charges related to illegally selling and advertising unlicensed medical devices, providing false statements to Health Canada inspectors, and interfering with seized products.

Moderna today announced the completion of construction of its state-of-the art mRNA manufacturing facility in Laval, Quebec.

Crescita Therapeutics Inc. today announced that it has agreed to acquire all of the non-real estate business assets of Occy Laboratory Inc., (“Occy”), a Laval-based manufacturer and distributor of high-quality dermocosmetic products (the “Transaction”).

Crescita Therapeutics Inc. today announced that it has concluded the asset purchase agreement (the “Purchase Agreement”) to acquire all of the non-real estate business assets of Occy Laboratory Inc. (“Occy”), a Laval-based manufacturer and distributor of high-quality dermocosmetic products (the “Transaction”).

Valbiotis announces the implementation of the TOTUM•63 mode of action clinical study by the Institute of nutrition and functional foods at Laval University in Quebec City, in partnership with Nestlé Health Science.

Endoceutics Inc., Université Laval, and CHU de Québec-Université Laval are pleased to announce that they have reached an agreement to resolve all their disputes with respect to economic benefits deriving from research.

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel of Laval University, a world expert on Tau pathology.

After having successfully treated 14 patients, a team of researchers at Université Laval’s Research Centre: The Tissue Engineering Laboratory (LOEX), led by professors at Université Laval and researchers at the CHU de Québec-Université Laval Research Centre, François A. Auger, Lucie Germain and Véronique Moulin, has just published their results pertaining to a new technique for burn patient treatment in the European Cells and Materials (eCM) Journal.